SEARCH

SEARCH BY CITATION

References

  • Adler C. M., Malhotra A. K., Elman I., Goldberg T., Egan M., Pickar D. and Breier A. (1999) Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am. J. Psychiatry 10, 16461649.
  • Balu D. T., Li Y., Puhl M. D., Benneyworth M. A., Basu A. C., Takagi S., Bolshakov V. Y. and Coyle J. T. (2013) Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc. Natl Acad. Sci. USA 110, E2400E2409.
  • Black M. D., Varty G. B., Arad M., Barak S., De Levie A., Boulay D., Pichat P., Griebel G. and Weiner I. (2009) Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology 202, 385396.
  • Bröer A., Wagner C. A., Lang F. and Bröer S. (2000) The heterodimeric amino acid transporter 4F2hc/y+LAT2 mediates arginine efflux in exchange with glutamine. Biochem. J. 355, 787795.
  • Brown J.M., Li J.J. and Sinz M.W. (2010) Antipsychotic agents in Burger's Medicinal Chemistry, Drug Discovery, and Development (Donald J., Abraham D. J., David P. and Rotella D. P.. eds), Seventh Edition, pp. 161218. John Wiley & Sons, Inc, Indianapolis, IN, USA.
  • Fukasawa Y., Segawa H., Kim J. Y., Chairoungdua A., Kim D. K., Matsuo H., Cha S. H., Endou H. and Kanai Y. (2000) Identification and Characterization of a Na+-independent Neutral Amino Acid Transporter That Associates with the 4F2 Heavy Chain and Exhibits Substrate Selectivity for Small Neutral d- and l-Amino Acids. J. Biol. Chem. 13, 96909698.
  • Gliddon C. M., Shao Z., LeMaistre J. L. and Anderson C. M. (2009) Cellular distribution of the neutral amino acid transporter subtype ASCT2 in mouse brain. J. Neurochem. 108, 372383.
  • Harada K., Nakato K., Yarimizu J. et al. (2012) A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. Eur. J. Pharmacol. 685, 5969.
  • Haughey H. M., Brown J. M., Wilkins D. G., Hanson G. R. and Fleckenstein A. E. (2000) Differential effects of methamphetamine on Na(+)/Cl(-)-dependent transporters. Brain Res. 863, 5965.
  • Helboe L., Egebjerg J., Møller M. and Thomsen C. (2003) Distribution and pharmacology of alanine-serine-cysteine transporter 1 (asc-1) in rodent brain. Eur. J. Neurosci. 8, 22272238.
  • Heresco-Levy U., Javitt D. C., Ermilov M., Mordel C., Horowitz A. and Kelly D. (1996) Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psychiatry 169, 610617.
  • Heresco-Levy U., Javitt D. C., Ebstein R., Vass A., Lichtenberg P., Bar G., Catinari S. and Ermilov M. (2005) D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiatry 57, 577585.
  • Javitt D. C., Zylberman I., Zukin S. R., Heresco-Levy U. and Lindenmayer J. P. (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry 151, 12341236.
  • Jentsch J. D., Redmond D. E. Jr, Elsworth J. D., Taylor J. R., Youngren K. D. and Roth R. H. (1997a) Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 27, 953955
  • Jentsch J. D., Tran A., Le D., Youngren K. D. and Roth R. H. (1997b) Subchronic Phencyclidine Administration Reduces Mesoprefrontal Dopamine Utilization and Impairs Prefrontal Cortical-Dependent Cognition in the Rat. Neuropsychopharmacology 17, 9299.
  • Kantrowitz J. T., Malhotra A. K., Cornblatt B., Silipo G., Balla A., Suckow R. F., D'Souza C., Saksa J., Woods S. W. and Javitt D. C. (2010) High dose D-serine in the treatment of schizophrenia. Schizophr. Res. 121, 125130.
  • Malhotra A. K., Pinals D. A., Weingartner H., Sirocco K., Missar C. D., Pickar D. and Breier A. (1996) NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14, 301307.
  • Nakauchi J., Matsuo H., Kim D. K. et al. (2000) Cloning and characterization of a human brain Na(+)-independent transporter for small neutral amino acids that transports D-serine with high affinity. Neurosci. Lett. 287, 231235.
  • Nikiforuk A., Kos T., Rafa D., Behl B., Bespalov A. and Popik P. (2011) Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine/NMDA receptor-dependent manner. Neuropharmacology 6, 262267.
  • Oliet S. H. and Mothet J. P. (2006) Molecular determinants of D-serine-mediated gliotransmission: from release to function. Glia 54, 726737.
  • Orozco-Ibarra M., Medina-Campos O. N., Sánchez-González D. J., Martínez-Martínez C. M., Floriano-Sánchez E., Santamaría A., Ramirez V., Bobadilla N. A. and Pedraza-Chaverri J. (2007) Evaluation of oxidative stress in D-serine induced nephrotoxicity. Toxicology 229, 123125.
  • Pineda M., Fernández E., Torrents D., Estévez R., López C., Camps M., Lloberas J., Zorzano A. and Palacín M. (1999) Identification of a membrane protein, LAT-2, that Co-expresses with 4F2 heavy chain, an L-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids. J. Biol. Chem. 274, 1973819744.
  • Rosenberg D., Artoul S., Segal A. C. et al. (2013) Neuronal D-serine and glycine release via the Asc-1 transporter regulates NMDA receptor-dependent synaptic activity. J. Neurosci. 33, 35333544.
  • Rutter A. R., Fradley R. L., Garrett E. M., Chapman K. L., Lawrence J. M., Rosahl T. W. and Patel S. (2007) Evidence from gene knockout studies implicates asc-1 as the primary transporter mediating d-serine reuptake in the mouse CNS. Eur. J. Neurosci. 25, 17571766.
  • Schell M. J., Brady R. O., Jr, Molliver M. E. and Snyder S. H. (1997) D-serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors. J. Neurosci. 17, 16041615.
  • Singh S. P. and Singh V. (2011) Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 25, 859885.
  • Stefani M. R. and Moghaddam B. (2005) Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol. Psychiatry 57, 433436.
  • Tsai G., Yang P., Chung L. C., Lange N. and Coyle J. T. (1998) D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 44, 10811089.
  • Utsunomiya-Tate N., Endou H. and Kanai Y. (1996) Cloning and functional characterization of a system ASC-like Na+-dependent neutral amino acid transporter. J. Biol. Chem. 271, 1488314890.
  • Verrey F., Closs E. I., Wagner C. A., Palacin M., Endou H. and Kanai Y. (2004) CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch. 477, 532542.
  • Williams R. E. and Lock E. A. (2004) D-serine-induced nephrotoxicity: possible interaction with tyrosine metabolism. Toxicology 20, 231238.
  • Xie X., Dumas T., Tang L. et al. (2005) Lack of the alanine-serine-cysteine transporter 1 causes tremors, seizures, and early postnatal death in mice. Brain Res. 1052, 212221.
  • Yanagida O., Kanai Y., Chairoungdua A. et al. (2001) Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim. Biophys. Acta 1514, 291292.